GEMEPROST

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C23H38O5
Molecular Weight	394.5448
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	2
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC\C=C\C(=O)OC

InChI

InChIKey=KYBOHGVERHWSSV-VNIVIJDLSA-N

InChI=1S/C23H38O5/c1-5-6-15-23(2,3)21(26)14-13-18-17(19(24)16-20(18)25)11-9-7-8-10-12-22(27)28-4/h10,12-14,17-18,20-21,25-26H,5-9,11,15-16H2,1-4H3/b12-10+,14-13+/t17-,18-,20-,21-/m1/s1

HIDE SMILES / InChI

Description
Sources: https://gp2u.com.au/static/pdf/C/CERVAGEM-PI.pdf

Gemeprost is a PGE1 analogue indicated for softening and dilatation of the cervix uteri prior to operative procedures or therapeutic abortion. The drug is marketed under the name Cervagem.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
uterine smooth muscle contraction 3 Target ID: GO:0070471 Sources: https://www.medicines.org.uk/emc/medicine/3968	Activator 1430

Conditions

Condition	Modality	Targets	Highest Phase	Product
Cervical dilatation 1 Sources: https://gp2u.com.au/static/pdf/C/CERVAGEM-PI.pdf	Primary		Approved 8429	CERVAGEM Approved Use For the softening and dilatation of the cervix uteri prior to transcervical, intrauterine operative procedures in the first trimester of pregnancy. Therapeutic termination of pregnancy in patients in the second trimester of gestation. Launch Date 1990

PubMed

Title	Date	PubMed
The use of prostaglandin E1 analogue pessaries in patients having first trimester induced abortions.	1980 Apr	7426498
Abortifacient effect and uterine cervix-dilating action of 16, 16-dimethyl trans delta 2 PGE1 methyl ester (ONO 802) in the form of a vaginal suppository (a randomized, double-blind, controlled study in the second trimester of pregnancy).	1982 Sep	6752961
A Gemeprost vaginal suppository for cervical priming prior to termination of first trimester pregnancy.	1984 Mar	6539662
The use of 16,16-dimethyl-trans delta 2 prostaglandin E1 methyl ester (gemeprost) vaginal pessaries for the termination of pregnancy in the early second trimester. A comparison with extra-amniotic prostaglandin E2.	1984 Nov	6594157
Midtrimester termination of pregnancy using intravaginal gemeprost (16, 16 dimethyl-trans delta 2 PGE1 methyl ester, cervagem).	1985 Apr	4035402
[Use of a new vaginal suppository: prostaglandin E1 analog Gemeprost for cervix maturation prior to abortion in the 1st trimester].	1985 Jun	3894147

Patents

Sample Use Guides

In Vivo Use Guide

One pessary to be inserted into the posterior vaginal fornix three hours before surgery.

Route of Administration: Vaginal

In Vitro Use Guide

Unknown

Name

Type

Language

GEMEPROST

Official Name

English

PREGLANDIN

Brand Name

English

Methyl (E)-7-[(1R,2R,3R)-3-hydroxy-2-[(E)-(3R)-3-hydroxy-4,4-dimethyl-1-octenyl]-5-oxocyclopentyl]-2-heptenoate

Systematic Name

English

GEMEPROST [MART.]

Common Name

English

gemeprost [INN]

Common Name

English

GEMEPROST [USAN]

Common Name

English

Gemeprost [WHO-DD]

Common Name

English

GEMEPROST [JAN]

Common Name

English

GEMEPROST [MI]

Common Name

English

PROSTA-2,13-DIEN-1-OIC ACID, 11,15-DIHYDROXY-16,16-DIMETHYL-9-OXO-, METHYL ESTER, (2E,11.ALPHA.,13E,15R)-

Common Name

English

SC-37681

Code

English

U-37026

Common Name

English

Classification Tree Code System Code

WHO-ATC

G02AD03